10.28
Amicus Therapeutics Inc stock is currently priced at $10.28, with a 24-hour trading volume of 295.65K.
It has seen a -3.40% decreased in the last 24 hours and a +10.21% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $10.70 pivot point. If it approaches the $10.25 support level, significant changes may occur.
Previous Close:
$10.64
Open:
$10.53
24h Volume:
295.65K
Market Cap:
$3.04B
Revenue:
$423.49M
Net Income/Loss:
$-147.07M
P/E Ratio:
-16.06
EPS:
-0.64
Net Cash Flow:
$-88.03M
1W Performance:
+2.32%
1M Performance:
+10.21%
6M Performance:
-17.41%
1Y Performance:
-22.68%
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
609-662-2000
Address
1 Cedar Brook Drive, Cranbury, NJ
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
Apr-13-22 | Resumed | Goldman | Neutral |
Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Nov-15-21 | Upgrade | Stifel | Hold → Buy |
Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
Jul-19-21 | Resumed | BTIG Research | Buy |
May-27-21 | Initiated | Needham | Hold |
May-21-21 | Initiated | UBS | Buy |
Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Mar-02-21 | Initiated | Stifel | Hold |
Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
Nov-11-20 | Initiated | Berenberg | Hold |
Jun-17-20 | Initiated | BTIG Research | Buy |
Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
Jun-17-19 | Initiated | H.C. Wainwright | Buy |
Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
Apr-05-19 | Initiated | Janney | Buy |
Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
Oct-29-18 | Initiated | Citigroup | Neutral |
Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
May-18-16 | Initiated | BofA/Merrill | Buy |
Apr-14-16 | Initiated | Robert W. Baird | Neutral |
Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Expected to Earn Q2 2024 Earnings of ($0.07) Per Share - Defense World
Defense World
Amicus Therapeutics Inc [FOLD] stock for 75000 USD was sold by Campbell Bradley L – Knox Daily - Knox Daily
Knox Daily
Amicus Therapeutics Inc (FOLD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
The InvestChronicle
Market Recap Check: Amicus Therapeutics Inc (FOLD)'s Positive Finish at 10.64, Up/Down 2.31 – DWinneX - The Dwinnex
The Dwinnex
Great Point Partners LLC Purchases 423,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
MarketBeat
Amicus Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.07) Per Share, Zacks Research Forecasts (NASDAQ:FOLD) - MarketBeat
MarketBeat
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Amicus Therapeutics Inc (FOLD) Revenue 2024
FOLD reported a revenue (TTM) of $423.49 million for the quarter ending March 31, 2024, a +25.74% rise year-over-year.
Amicus Therapeutics Inc (FOLD) Net Income 2024
FOLD net income (TTM) was -$147.07 million for the quarter ending March 31, 2024, a +27.99% increase year-over-year.
Amicus Therapeutics Inc (FOLD) Cash Flow 2024
FOLD recorded a free cash flow (TTM) of -$88.03 million for the quarter ending March 31, 2024, a +32.89% increase year-over-year.
Amicus Therapeutics Inc (FOLD) Earnings per Share 2024
FOLD earnings per share (TTM) was -$0.49 for the quarter ending March 31, 2024, a +30.00% growth year-over-year.
About Amicus Therapeutics Inc
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Cap:
|
Volume (24h):